港股收評：恒科指止步3連跌，醫藥、茶飲股強勢，黃金股低迷
5月27日，恒生科技指數收升0.48%，止步3連跌行情；恒生指數、國企指數分別上升0.43%及0.38%，交易量延續低迷。
盤面上，作為市場風向標的大型科技股普遍回暖；創新藥再迎重要催化！頂級腫瘤學年會召開在即，生物醫藥股全天表現強勢；在線教育股、航空股、啤酒股、芯片股、體育用品股齊升。黃金股多數表現低迷，汽車股再度下跌，汽車經銷商股、汽車零件股跟跌。此外，派格生物醫藥-B首日上市大跌近26%。
具體來看：
科技股普升，美團績後升超2%，網易、阿里、小米、騰訊登紛紛收升，京東跌1%。個股消息面上，美團Q1營收同比增長18.1%，經調整淨利潤同比增長46.2%；另外今日美團宣佈聯合百大餐飲、零售品牌，於5月28日至6月18日開啟618大促活動。
生物醫藥、醫藥外包概念走強，君實生物大升超12%，藥明合聯升超8%。消息上，多家創新藥企業宣佈將在5月30日至6月3日舉辦的2025年美國臨牀腫瘤學會(ASCO)年會上展示創新藥物研究成果。券商機構認為，目前我國創新藥進入成果兑現階段，研發進展催化較多，有望持續作為2025年醫藥板塊投資主線。
茶飲、酒精飲料、食品股等大消費方向大升。蜜雪集團、茶百道升超9%，古茗升超7%。消息面上，大和近期研報指出，對蜜雪集團的增長前景充滿信心，基於其獨一無二的規模經濟、在大眾市場的領先地位，以及海外擴張的潛力。該行指出，四月外賣平台競爭亦有助帶動蜜雪集團的同店銷售，預計4月同店銷售增長逾10%，令市場對集團的預測持續上調，並支持近期股價。
航空股上升，中國東方航空股股份升超4%，中國航空升超3%，中國南方航空股份升超2%。近日六大航空公司陸續披露2025年前4月經營數據情況，各大航司4月旅客週轉量、客運運力投入同比均上升。
汽車股延續跌勢，蔚來跌超2%，吉利汽車、比亞迪股份等跌超1%。消息面上，比亞迪大降價引發市場對價格戰的擔憂，電動車內卷加劇，行業情緒緊繃。摩根士丹利指出，此次降價釋放出終端市場壓力巨大的信號，投資者情緒可能進一步悲觀。
黃金及貴金屬股下挫，赤峯黃金、招金礦業跌超4%，紫金礦業跌超3%。消息面上，現貨黃金較日高下跌約50美元，向下觸及3300美元/盎司，日內跌1.26%。現貨白銀回落至33美元/盎司下方，日內跌1.40%。
今日，南向資金淨買入119.75億港元，其中港股通（滬）淨買入81.67億港元，港股通（深）淨買入38.08億港元。
展望後市，瑞銀分析師指出，今年年初Deepseek推出，令科技股帶動港股上升。雖然貿易戰令港股表現稍為回落，但現時已恢復，IPO數量亦有增加，港股整體利潤有提升，基本面較宏觀經濟好。
該行對港股持審慎樂觀態度，今年底恒指目標24500點。目前港股估值位處歷史平均水平，今年較看好科技股和高股息、防守性高的基建及銀行股，而貿易戰帶來的不穩定性依然持續，需要繼續觀察。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
